Evogene (EVGN) Operating Leases (2019 - 2025)
Evogene (EVGN) posted Operating Leases of $2.2 million for Q4 2025, up 19.13% sequentially from $1.8 million in Q3 2025, and down 12.19% YoY from $2.5 million in Q4 2024.
Evogene (EVGN) Operating Leases (2019 - 2025) Analysis & Trends
Evogene has reported Operating Leases for 7 years, with the latest figure at $2.2 million in Q4 2025.
- Quarterly Operating Leases fell 12.19% year-over-year to $2.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.2 million (down 12.19% YoY) and the FY2025 annual result came in at $2.2 million, down 12.19% from the prior year.
- Operating Leases climbed to $2.2 million in Q4 2025 per EVGN's latest filing, from $1.8 million in the prior quarter.
- Over five years, Operating Leases peaked at $2.7 million in Q4 2021 and troughed at $417000.0 in Q3 2024.
- A 5-year average of $1.5 million and a median of $1.6 million in 2021 frame the typical range for Operating Leases.
- The sharpest annual moves came in 2024 and 2025: Operating Leases slumped 51.17% in 2024, then soared 342.45% in 2025.
- Over 5 years, Operating Leases stood at $2.7 million in 2021, then slumped by 31.96% to $1.8 million in 2022, then slumped by 37.33% to $1.1 million in 2023, then jumped by 119.95% to $2.5 million in 2024, then dropped by 12.19% to $2.2 million in 2025.
- According to Business Quant data, Operating Leases over the past three periods registered $2.2 million, $1.8 million, and $2.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.20 Mn |
| Sep 30, 2025 | 1.85 Mn |
| Jun 30, 2025 | 1.98 Mn |
| Mar 31, 2025 | 1.92 Mn |
| Dec 31, 2024 | 2.50 Mn |
| Sep 30, 2024 | 417,000.00 |
| Jun 30, 2024 | 558,000.00 |
| Mar 31, 2024 | 715,000.00 |
| Dec 31, 2023 | 1.14 Mn |
| Sep 30, 2023 | 854,000.00 |
| Jun 30, 2023 | 894,000.00 |
| Mar 31, 2023 | 904,000.00 |
| Dec 31, 2022 | 1.82 Mn |
| Sep 30, 2022 | 1.04 Mn |
| Jun 30, 2022 | 1.37 Mn |
| Mar 31, 2022 | 1.54 Mn |
| Dec 31, 2021 | 2.67 Mn |
| Sep 30, 2021 | 1.79 Mn |
| Jun 30, 2021 | 1.60 Mn |
| Mar 31, 2021 | 1.59 Mn |